SynthesisSaudi medical journal2025
Phase IV clinical trials for the treatment of non-small cell lung carcinoma (NSCLC): A systemic review from 2020-2025.
Synthesis in Saudi medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-receptor tyrosine kinase signaling pathways and therapeutic implications.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate and provide evidence on drugs investigated in completed phase IV clinical trials for adult non-small cell lung carcinoma (NSCLC) therapy, primarily focusing on treatment objectives and adverse effects.
methodsClinical research studies from January 2020 to January 2025 were systematically reviewed using the "ClinicalTrials.gov" database. The inclusion criteria focused on publicly available, relevant, and completed Phase IV studies limited to "Clinicaltrials.gov", while those not meeting these specifications were excluded. As of 3 January 2025, a total of 7,541 Phase IV clinical trials were available on "ClinicalTrials.gov", of which 121 were related to NSCLC.
resultsSix of these clinical studies met the requirements for inclusion in the current investigation. The pharmacological agents investigated in these Phase IV trials were dacomitinib, lorlatinib, durvalumab, osimertinib, and a combination of rivaroxban and sotorasib. Treatment options for NSCLC remain limited due to its complex nature and frequent co-occurrence with other respiratory infections.
conclusionThe studies reviewed reported high rates of adverse events, alongside reduced subjective outcomes and faster response periods. This warrants for continuous research to develop safer and more efficient therapy methods for NSCLC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.